FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.8.4  |  FHIR Version n/a  User: [n/a]

1495581000168106: List of Medicines for Brand Consideration reference set (foundation metadata concept)


Status: current, Primitive. Date: 30-Sep 2020. Module: Third party reference set module

Descriptions:

Id Description Lang Type Status Case? Module
4462321000168116 List of Medicines for Brand Consideration reference set (foundation metadata concept) en Fully specified name Active Initial character case insensitive Third party reference set module
4462331000168118 List of Medicines for Brand Consideration reference set en Synonym Active Initial character case insensitive Third party reference set module
4462411000168119 List of Medicines for Brand Consideration (LMBC) reference set en Synonym Active Initial character case insensitive Third party reference set module
4462641000168118 <p>Supports the identification of AMT Medicinal Product Unit of Use (MPUU) and Medicinal Product Pack (MPP) concepts associated with the List of Medicines for Brand Consideration (LMBC) that forms part of the Active Ingredient Prescribing initiative. Under the <i>National Health (Pharmaceutical Benefits) Regulations 2017</i>, the <i>Repatriation Pharmaceutical Benefits Scheme Instrument 2013</i> and <i>MRCA Pharmaceutical Benefits Scheme Instrument 2013</i>, all PBS and RPBS prescriptions must be prepared by active ingredient, the brand may additionally be identified if a prescriber considers it necessary. The LMBC supports prescribers' decision-making regarding the inclusion of brand on a prescription.</p><p>This reference set can be used by prescribing software vendors to identify medications for brand consideration to meet Active Ingredient Prescribing requirements.</p><p><b>Target Client:&nbsp;</b>This reference set was developed by the National Clinical Terminology Service for the Australian Government Department of Health and Aged Care to support the Active Ingredient Prescribing initiative, and can be used by developers to assist with the requirements.</p> en Definition Active Case sensitive Third party reference set module


1324 members. Search Members:

Expanded Value Set


Outbound Relationships Type Target Active Characteristic Refinability Group Values
List of Medicines for Brand Consideration reference set Is a Reference sets for Medications true Inferred relationship Some
List of Medicines for Brand Consideration reference set Is a Simple type reference set true Inferred relationship Some
List of Medicines for Brand Consideration reference set Developed by Australian Government Department of Health and Aged Care true Inferred relationship Some 1570063879

Members
itraconazole 50 mg capsule, 15
itraconazole 50 mg capsule, 28
itraconazole 50 mg capsule, 60 capsules (medicinal product pack)
itraconazole 50 mg capsule, 7
latanoprost 0.005% + timolol 0.5% eye drops
latanoprost 0.005% + timolol 0.5% eye drops, 2.5 mL
latanoprost 0.005% + timolol 0.5% eye drops, 3 x 2.5 mL
latanoprost 0.005% eye drops
latanoprost 0.005% eye drops, 1 mL
latanoprost 0.005% eye drops, 2.5 mL
latanoprost 0.005% eye drops, 3 x 2.5 mL
latanoprost 0.005% eye drops, 6 x 2.5 mL
leuprorelin acetate 22.5 mg modified release injection, chamber
leuprorelin acetate 22.5 mg modified release injection, syringe
leuprorelin acetate 30 mg modified release injection, chamber
leuprorelin acetate 30 mg modified release injection, syringe
leuprorelin acetate 45 mg modified release injection, chamber
leuprorelin acetate 45 mg modified release injection, syringe
leuprorelin acetate 7.5 mg modified release injection, chamber
leuprorelin acetate 7.5 mg modified release injection, syringe
levothyroxine sodium 100 microgram tablet
levothyroxine sodium 100 microgram tablet, 100
levothyroxine sodium 100 microgram tablet, 2 x 100
levothyroxine sodium 100 microgram tablet, 200
levothyroxine sodium 100 microgram tablet, 90
levothyroxine sodium 125 microgram tablet
levothyroxine sodium 125 microgram tablet, 100
levothyroxine sodium 125 microgram tablet, 200
levothyroxine sodium 125 microgram tablet, 90
levothyroxine sodium 200 microgram tablet
levothyroxine sodium 200 microgram tablet, 100
levothyroxine sodium 200 microgram tablet, 2 x 100
levothyroxine sodium 200 microgram tablet, 200
levothyroxine sodium 200 microgram tablet, 90
levothyroxine sodium 50 microgram tablet
levothyroxine sodium 50 microgram tablet, 100
levothyroxine sodium 50 microgram tablet, 2 x 100
levothyroxine sodium 50 microgram tablet, 200
levothyroxine sodium 50 microgram tablet, 90
levothyroxine sodium 75 microgram tablet
levothyroxine sodium 75 microgram tablet, 100
levothyroxine sodium 75 microgram tablet, 2 x 100
levothyroxine sodium 75 microgram tablet, 200
levothyroxine sodium 75 microgram tablet, 90
lithium carbonate 250 mg tablet
lithium carbonate 250 mg tablet, 100
lithium carbonate 250 mg tablet, 1000
lithium carbonate 250 mg tablet, 200
lithium carbonate 450 mg modified release tablet
lithium carbonate 450 mg modified release tablet, 100
mesalazine 1 g/application enema, 1 application
mesalazine 1 g/application enema, 14 applications
mesalazine 1 g/100 mL enema
mesalazine 1 g/100 mL enema, 7 x 100 mL
mesalazine 1 g enteric tablet
mesalazine 1 g enteric tablet, 10
mesalazine 1 g enteric tablet, 100
mesalazine 1 g enteric tablet, 150
mesalazine 1 g enteric tablet, 20 tablets (medicinal product pack)
mesalazine 1 g enteric tablet, 50
mesalazine 1 g enteric tablet, 60
mesalazine 1 g enteric tablet, 90
mesalazine 1 g modified release granules, sachet
mesalazine 1 g modified release granules, 100 x 1 g sachets (medicinal product pack)
mesalazine 1 g modified release granules, 120 sachets
mesalazine 1 g modified release granules, 150 sachets
mesalazine 1 g modified release granules, 30 sachets
mesalazine 1 g modified release granules, 50 sachets
mesalazine 1 g modified release tablet
mesalazine 1 g modified release tablet, 20
mesalazine 1 g modified release tablet, 60
mesalazine 1 g suppository
mesalazine 1 g suppository, 28
mesalazine 1 g suppository, 30
mesalazine 1.2 g modified release tablet
mesalazine 1.2 g modified release tablet, 12
mesalazine 1.2 g modified release tablet, 120
mesalazine 1.2 g modified release tablet, 60
mesalazine 1.5 g modified release granules, sachet
mesalazine 1.5 g modified release granules, 100 sachets
mesalazine 1.5 g modified release granules, 60 x 1.5 g sachets (medicinal product pack)
mesalazine 1.6 g enteric tablet
mesalazine 1.6 g enteric tablet, 30
mesalazine 1.6 g enteric tablet, 60
mesalazine 1.6 g enteric tablet, 90
mesalazine 2 g modified release granules, 10 sachets
mesalazine 2 g modified release granules, 15 sachets
mesalazine 2 g modified release granules, sachet
mesalazine 2 g modified release granules, 60 sachets
mesalazine 250 mg enteric tablet
mesalazine 250 mg enteric tablet, 100
mesalazine 3 g modified release granules, sachet
mesalazine 3 g modified release granules, 30 sachets
mesalazine 3 g modified release granules, 50 sachets
mesalazine 3 g modified release granules, 6 sachets
mesalazine 4 g modified release granules, 30 sachets
mesalazine 4 g modified release granules, sachet
mesalazine 500 mg enteric tablet
mesalazine 500 mg enteric tablet, 10
mesalazine 500 mg enteric tablet, 100
mesalazine 500 mg modified release granules, 100 sachets

Start Previous Page 10 of 14 Next End


Reference Sets

Australian dialect reference set

Reference set descriptor

Back to Start